Stonegate Capital Partners has updated its coverage on NU Skin Enterprises Inc. (NYSE: NUS), following the company's fourth quarter 2025 financial results. NUS reported revenue of $370.3 million, adjusted net income of $14.5 million, and adjusted earnings per share (EPS) of $0.29. These figures came in slightly below Stonegate's estimates of $380.2 million in revenue, $15.1 million in adjusted net income, and $0.30 adjusted EPS. However, the results were at the low end of revenue guidance and the high end of EPS guidance, indicating effective cost management.
The Rhyz segment contributed $48.52 million in revenue, comprising $42.45 million from Manufacturing and $6.07 million from Rhyz Other. The core Nu Skin business maintained a strong gross margin of 77.6%, benefiting from disciplined spending as selling expenses declined to 40.8% of core business revenue. Management attributed the better-than-expected EPS performance to strategic initiatives, including active penetration into India and other emerging markets, overall margin expansion, and a one-time tax benefit.
Looking ahead, NU Skin is advancing its Prism iO rollout in the first half of 2026, with a full launch expected in the second half. The company has also begun pre-launch activities in India, with a full market opening anticipated in the second half of 2026. For fiscal year 2026, management provided EPS guidance with a midpoint of $1.00. Despite weaker-than-expected top-line results, the company remains focused on executing its strategic initiatives to drive long-term growth.
The full announcement, including downloadable images and bios, is available here. Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets, offers investment banking services for public and private companies.
